Dr. Wolchok on Concurrent Ipilimumab and Nivolumab

Jedd D. Wolchok, MD, PhD
Published: Wednesday, Jun 19, 2013

Jedd D. Wolchok, MD, PhD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Ipilimumab was approved by the FDA to treat metastatic melanoma in 2011 based on the phase III demonstration of an extension in survival. Additionally, a phase I trial showed that nivolumab was capable of effectively eliciting durable clinical responses. These data, and other research, led to the phase I trial exploring the combination.

In the trial, the overall response rate in the concurrent treatment cohorts was 40%. Additionally, Wolchok notes, a significant number of patients experienced rapid and deep regressions with 80% showing signs of a reduction in tumor burden after 12 weeks of treatment. Patients receiving the highest dose (1 mg/kg of nivolumab and 3 mg/kg of ipilimumab) experienced an objective response rate of 53% with 18% demonstrating a complete response.

This early phase trial demonstrated significant activity for the combination of ipilimumab and nivolumab. Based on this data, Wolchok notes, a phase III trial has been launched comparing the combination to single agent nivolumab or ipilimumab.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting

Jedd D. Wolchok, MD, PhD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Ipilimumab was approved by the FDA to treat metastatic melanoma in 2011 based on the phase III demonstration of an extension in survival. Additionally, a phase I trial showed that nivolumab was capable of effectively eliciting durable clinical responses. These data, and other research, led to the phase I trial exploring the combination.

In the trial, the overall response rate in the concurrent treatment cohorts was 40%. Additionally, Wolchok notes, a significant number of patients experienced rapid and deep regressions with 80% showing signs of a reduction in tumor burden after 12 weeks of treatment. Patients receiving the highest dose (1 mg/kg of nivolumab and 3 mg/kg of ipilimumab) experienced an objective response rate of 53% with 18% demonstrating a complete response.

This early phase trial demonstrated significant activity for the combination of ipilimumab and nivolumab. Based on this data, Wolchok notes, a phase III trial has been launched comparing the combination to single agent nivolumab or ipilimumab.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x